Immunotherapy & Immuno-Oncology
Part of Healthcare - Oncology
 JNJ | Johnson & Johnson | $0.6t | $266.25 | +1.0% | 4.0M |
 ABBV | ABBVIE INC. | $464.4b | $287.04 | +0.4% | 2.7M |
 MRK | Merck & Co., Inc. | $356.0b | $140.63 | -3.1% | 10.1M |
 AZN | AstraZeneca PLC | $243.3b | $170.88 | +0.8% | 2.3M |
 AMGN | Amgen Inc | $217.9b | $443.01 | +1.3% | 1.5M |
 BMY | Bristol-Myers Squibb Co. | $124.9b | $61.37 | +0.2% | 4.7M |
 MRNA | Moderna, Inc. Common Stock | $75.9b | $195.70 | -0.7% | 15.8M |
 REGN | Regeneron Pharmaceuticals Inc | $75.7b | $809.64 | +0.4% | 322.4K |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | $25.5b | $64.77 | +1.4% | 2.8M |
 IBRX | ImmunityBio, Inc. Common Stock | $10.9b | $7.83 | -4.7% | 10.2M |
 ACLX | Arcellx, Inc. Common Stock | $6.7b | $115.06 | -0.0% | 16.1M |
 IOVA | Iovance Biotherapeutics, Inc. Common Stock | $6.4b | $13.84 | -2.2% | 6.7M |
 CGON | CG Oncology, Inc. Common stock | $6.0b | $61.60 | -0.2% | 425.3K |
 RCUS | Arcus Biosciences, Inc. | $3.1b | $17.46 | -6.0% | 2.3M |
 PGEN | Precigen, Inc. Common Stock | $3.1b | $6.05 | -2.3% | 2.1M |
 SLS | SELLAS Life Sciences Group, Inc. Common Stock | $2.4b | $11.34 | -1.6% | 2.8M |
 XNCR | Xencor, Inc. | $1.8b | $29.27 | +16.0% | 8.6M |
 SNDX | Syndax Pharmaceuticals, Inc. | $1.6b | $13.21 | -1.5% | 1.5M |
 NKTR | Nektar Therapeutics | $1.5b | $38.21 | +0.6% | 333.1K |
 INBX | Inhibrx Biosciences, Inc. Common Stock | $1.4b | $88.57 | -5.3% | 227.1K |
 OMER | Omeros Corporation | $1.3b | $16.40 | -1.7% | 590.4K |
 REPL | Replimune Group, Inc. | $1.2b | $12.50 | +8.9% | 1.7M |
 BCAX | Bicara Therapeutics Inc. Common Stock | $1.2b | $16.89 | -1.1% | 935.5K |
 IMTX | Immatics N.V. Ordinary Shares | $1.2b | $7.40 | -2.1% | 653.8K |
 JANX | Janux Therapeutics, Inc. Common Stock | $1.0b | $16.70 | 0.0% | 274.8K |
 CGEM | Cullinan Therapeutics, Inc. Common Stock | $1.0b | $15.25 | +1.3% | 279.8K |
 CRVS | Corvus Pharmaceuticals, Inc. | $0.9b | $10.45 | -0.9% | 821.1K |
 CADL | Candel Therapeutics, Inc. Common Stock | $0.8b | $7.91 | -3.0% | 764.7K |
 AURA | Aura Biosciences, Inc. Common Stock | $0.6b | $6.18 | -1.7% | 744.9K |
 CTMX | CytomX Therapeutics, Inc. | $0.6b | $2.23 | -4.1% | 4.7M |
 CBIO | Crescent Biopharma, Inc. Common Stock | $0.5b | $12.76 | -0.4% | 172.2K |
 AGEN | Agenus Inc. | $377.6m | $6.24 | -2.7% | 582.8K |
 INDP | Indaptus Therapeutics, Inc. Common Stock | $317.1m | $3.34 | +5.5% | 348.7K |
 GLSI | Greenwich LifeSciences, Inc. | $249.2m | $17.14 | +8.5% | 101.6K |
 MGNX | MacroGenics, Inc. | $228.0m | $2.16 | -2.9% | 2.5M |
 CGEN | Compugen Ltd | $218.8m | $1.88 | -3.4% | 332.4K |
 CUE | Cue Biopharma, Inc. | $185.8m | $18.42 | -1.4% | 172.5K |
 CHRS | Coherus Oncology, Inc. Common Stock | $179.2m | $1.01 | 0.0% | 640.3K |
 ALXO | ALX Oncology Holdings Inc. Common Stock | $168.7m | $1.13 | -3.4% | 934.0K |
 VRXA | Veraxa Biotech AG Ordinary Shares | $157.0m | $0.98 | -1.5% | 159.2K |
 CMPX | Compass Therapeutics, Inc. Common Stock | $154.3m | $0.74 | -1.0% | 1.9M |
 HURA | TuHURA Biosciences, Inc. Common Stock | $121.7m | $2.04 | -6.0% | 629.7K |
 GNLX | Genelux Corporation Common Stock | $115.8m | $1.94 | -4.5% | 490.4K |
 ANIX | Anixa Biosciences, Inc. | $102.6m | $2.92 | -1.3% | 131.7K |
 ONCY | Oncolytics Biotech, Inc. Common Shares | $80.5m | $0.48 | -5.8% | 693.0K |
 MAIA | MAIA Biotechnology, Inc. | $73.5m | $1.12 | -3.5% | 268.3K |
 XBIT | XBiotech Inc | $66.8m | $1.89 | -5.7% | 135.0K |
 XLO | Xilio Therapeutics, Inc. Common Stock | $59.3m | $7.16 | -5.0% | 33.2K |
 PDSB | PDS Biotechnology Corporation Common Stock | $54.4m | $1.07 | -3.6% | 2.2M |
 INMB | INmune Bio Inc. Common stock | $53.6m | $1.46 | -2.7% | 151.8K |